Carlos Malvestutto, MD, MPH, FIDSA is an Associate Professor of Clinical Medicine in the Division of Infectious Diseases at the Ohio State University Wexner Medical Center.
He is the Clinical Research Site Leader of the OSU Infectious Diseases Clinical Trials Unit. He has authored over 80 peer-reviewed publications.
Dr. Malvestutto’s research has focused on cardiovascular complications of HIV as well as HIV cure strategies using broadly neutralizing antibodies. He is a co-Vice Chair of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) and has been an investigator and leader of various multi-center clinical trials.
He is a member of the Reservoirs, Remission and Cure Transformative Science Group of the Advancing Clinical Therapeutics Globally (ACTG) network and of the Cardiovascular Working Group of the MACS/WIHS Combined Cohort Study. Dr. Malvestutto serves on the Board of Directors of the HIV Medical Association (HIVMA) of the Infectious Diseases Society of America (IDSA).
